FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript
FDA medical oncologists discuss the agency ’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Ovarian cancer hope after discovery of six types of cell that trigger the 'silent killer'
By detecting the abnormal cells in the fallopian tube lining, ovarian cancer could be diagnosed earlier. Currently just over a third of English patients live for five years after diagnosis of the 'silent killer'. (Source: the Mail online | Health)
Source: the Mail online | Health - February 10, 2020 Category: Consumer Health News Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Disease profile in England: Incidence, mortality, stage and survival for ovary, fallopian tube and primary peritoneal carcinomas
This report provides a detailed insight into the status of ovarian cancer in England. It is the first report from the Cancer Audit Feasibility Pilot project which runs for two years and includes details of disease incidence, mortality and survival. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 10, 2020 Category: Consumer Health News Source Type: news
Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Discouraging OS Results With Bevacizumab in Ovarian Cancer
Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Role of PARP Inhibitors in BRCA-Related Malignancies Role of PARP Inhibitors in BRCA-Related Malignancies
Review the pharmacology of PARP inhibitors and their use in BRCA-mutated malignancies including breast, ovarian, fallopian tube, and primary peritoneal cancers.U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2018 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news
Crosstalk between fallopian tube, ovary may drive the spread of ovarian cancer
(University of Illinois at Chicago) New research shows that cancer cells in the fallopian tube affect normal chemical signaling between reproductive tissues and stimulate the release of norepinephrine from the ovary, causing cancer cells to migrate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 9, 2018 Category: Cancer & Oncology Source Type: news
Ovarian Epithelial Fallopian Tube Cancer Treatment
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 26, 2018 Category: General Medicine Source Type: news
FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news
Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients.
The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
That means more women with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2018 Category: Biotechnology Authors: Greg Avery Source Type: news
Quiz: Genetic Risk Evaluation for Fallopian Tube Cancer?
Should a patient with fallopian tube cancer undergo genetic risk evaluation? What is essential in post-treatment monitoring of ovarian, fallopian tube, and primary peritoneal cancers? Take this multiquestion quiz to find out. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers Quiz Source Type: news
Ending ovarian cancer without triggering menopause
Ovarian cancer doesn't actually begin in the ovaries. Instead, cancer cells start growing in the fallopian tubes, say researchers who believe that removing the tubes could prevent the spread of the deadly disease.
Scientists at the NYU Perlmutter Cancer and Center MD Anderson Cancer Center in Houston found precursor lesions in women with ovarian cancer were most genetically similar to fallopian tube tissue, The Wall Street Journal reported.
A second study at Johns Hopkins University found that… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 13, 2018 Category: Pharmaceuticals Authors: Anne Stych Source Type: news
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients.
The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 6, 2017 Category: Pharmaceuticals Authors: Greg Avery Source Type: news
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients.
The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 6, 2017 Category: Biotechnology Authors: Greg Avery Source Type: news
